Re-evaluation of secondary amenorrheic patients one year after initial diagnosis: a prospective study.
OBJECTIVE
The aim of the study was to re-evaluate women with secondary amenorrhea one year after the first visit evaluation.


METHODS
One hundred and seventy-five women with secondary amenorrhea were evaluated on the first visit. Their ages ranged from 18 to 29. Secondary amenorrhea was defined by the absence of menses for more than 3 months after excluding pregnancy. Women who were attempting to conceive were excluded from the study. 1) One hundred and two women were anovulatory (2) 36 had hypogonadotropic hypogonadism, 3) 11 had hypergonadotropic hypogonadism, and 4) 21 had hyperprolactinemia, 5) and five fell into other categories. The one hundred and forty-nine women in categories 1) to 3) were followed up for one year after the first diagnosis was made. A monthly progestational agent or HRT (hormone replacement therapy) was given to women with anovulation or hypogonadism, respectively.


RESULTS
Of the 149 women in categories 1) to 3), 100 could be evaluated one year after the first diagnosis. There were 31 women whose diagnosis was changed. Anovulation changed to hypogonadotropic hypogonadism in 11 women, oligomenorrhea in four, and normal ovulatory cycle in two. Hypogonadotropic hypogonadism changed to anovulation in nine women, and to normal ovulatory cycle in one. Hypergonadotropic hypogonadism changed to normal ovulatory cycle in two women.


CONCLUSIONS
A significant finding is that approximately one third of the women initially diagnosed with secondary amenorrhea, upon re-evaluation within one year had their diagnosis changed. Therefore evaluation of amenorrhea at an appropriate time is critical for proper management.
Matsumoto
Joji
J
Ogawa Red Cross Hospital, 1525 Ogawa, Ogawa-machi, Hiki, Saitama 355-0397, Japan. jkrm@nms.ac.jp
Hata
Toshio
T
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000858:Anovulation / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D003276:Contraceptives, Oral / Q000008:administration & dosage; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D007006:Hypogonadism / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D011446:Prospective Studies; D013997:Time Factors
D003276:Contraceptives, Oral; D004966:Estrogens, Conjugated (USP); D017258:Medroxyprogesterone Acetate